The groundbreaking success of Sildenafil undeniably transformed the medication landscape, but betting in companies heavily reliant on unbranded versions presents a challenging picture. While early earnings were significant, the expiration of patents and the emergence of discounted alternatives have eroded sales. Thus, a thorough assessment of prese